



Un-audited Financial Results for the three and nine months period ended 31st December, 2010


₹ lakhs

	THREE MONTHS ENDED 31 ST DECEMBER, 2010 (REVIEWED)	CORRESPONDING THREE MONTHS IN THE PREVIOUS YEAR	YEAR TO DATE FIGURES FOR THE CURRENT YEAR (REVIEWED)	YEAR TO DATE FIGURES FOR THE PREVIOUS YEAR (UN-AUDITED)	PREVIOUS ACCOUNTING YEAR 31-03-2010
01. Net Sales / Income from Operations (including Excise Duty & Sales Tax)	7968	7483	25082	20953	29124
02. Other Operating Income	1131	825	2453	2518	3459
03. TOTAL INCOME	9099	8308	27535	23471	32583
04. EXPENDITURE					
a) Increase / Decrease in Stock-in-Trade and work-in-progress	-196	224	-692	-359	335
b) Consumption of Raw Materials	2179	2129	7303	6773	8094
c) Purchase of traded goods	407	263	1036	1179	1313
d) Employees Cost	1276	952	3888	2928	4217
e) Depreciation	322	330	1027	975	1245
f) Other Expenditure	3097	2465	8965	6618	10035
g) TOTAL	7085	6363	21527	18114	25239
05. Profit from Operations before other income, interest	2014	1945	6008	5357	7344
06. Other Income	26	33	87	150	211
07. Interest	345	386	1107	1146	1469
08. Profit / (Loss) from ordinary activities before tax	1695	1592	4988	4361	6086
09. Tax expense, including deferred tax	455	383	1232	1027	1320
10. Net Profit / Loss (-) from ordinary activities after tax	1240	1209	3756	3334	4766
11. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	2815	2815	2815	2815	2815
12. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year					27328
13. Earnings per share - Basic and diluted EPS before and after extraordinary item (Rs.)	4.41/4.41	4.30/4.30	13.34/13.34	11.84/11.84	16.95/16.93
14. Public Shareholding:					
a) Number of Shares	10,502,055	10,619,755	10,502,055	10,619,755	10,530,255
b) Percentage of Shareholding	37.31	37.73	37.31	37.73	37.41
15. Promoters and Promoter Group Shareholding					
a) Pledged / Encumbered - No. of shares	1,050,000	1,050,000	1,050,000	1,050,000	1,050,000
Percentage (as a % of the total shareholding of promoter and promoter group)	5.95	5.99	5.95	5.99	5.96
Percentage (as a % of the total share capital of the company)	3.73	3.73	3.73	3.73	3.73
b) Non - encumbered - No. of shares	16,595,897	16,478,197	16,595,897	16,478,197	16,567,697
Percentage (as a % of the total shareholding of promoter and promoter group)	94.05	94.00	94.05	94.00	94.04
Percentage (as a % of the total share capital of the company)	58.96	58.54	58.96	58.54	58.86

The above un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Monday, the 14th February, 2011. There are no exceptional and extraordinary items to be reported for the period under review. In respect of matters referred to in the limited review report by the Auditors relating to non-accounting of minimum alternative tax credit amounting to Rs. 357.73, Rs. 994.09 and Rs. 1606.08 lakhs for the quarter ended on 31st December, 2010, nine months ended on 31st December, 2010 and for the year ended 31st March, 2010 respectively, the company will review the position at the end of the financial year ending 31 March 2011.

Dated at Hyderabad, this, the 14th day of February, 2011.

for and on behalf of the Board of Directors,
NATCO Pharma Limited


V. C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2010

Pending as on 01-10-2010	Nil
Received during the quarter	56
Resolved during the quarter	56
Pending as on 31-12-2010	Nil



Un-audited Financial Results (consolidated) for the three and nine months period ended 31st December, 2010


₹ in lakhs

	THREE MONTHS ENDED 31 ST DECEMBER, 2010 (REVIEWED)	CORRESPONDING THREE MONTHS IN THE PREVIOUS YEAR	YEAR TO DATE FIGURES FOR THE CURRENT YEAR (REVIEWED)	YEAR TO DATE FIGURES FOR THE PREVIOUS YEAR (UN-AUDITED)	PREVIOUS ACCOUNTING YEAR 31-03-2010
01. Net Sales / Income from Operations (including Excise Duty & Sales Tax)	10703	10892	34315	32261	44028
02. Other Operating Income	1131	814	2462	2488	3459
03. TOTAL INCOME	11834	11706	36777	34749	47487
04. EXPENDITURE					
a) Increase / Decrease in Stock-in-Trade and work-in-progress	-196	224	-692	-359	335
b) Consumption of Raw Materials	4181	4912	14529	16048	20091
c) Purchase of traded goods	407	263	1036	1179	1313
d) Employees Cost	1590	1295	4854	3982	5739
e) Depreciation	330	341	1073	1009	1306
f) Other Expenditure	3427	2681	9829	7396	11208
g) TOTAL	9739	9716	30629	29255	39992
05. Profit from Operations before other income, interest	2095	1990	6148	5494	7495
06. Other Income	26	29	90	176	276
07. Interest	366	417	1175	1250	1612
08. Less : Minority Interest	-94	5	-129	10	-69
09. Profit / Loss (-) from ordinary activities before tax, after minority interest	1849	1597	5192	4410	6228
10. Tax expense, including deferred tax	477	383	1279	1042	1366
11. Net Profit / Loss (-) from ordinary activities after tax	1372	1214	3913	3368	4862
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	2815	2815	2815	2815	2815
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year					27399
14. Earnings per share Basic and diluted EPS before and after extraordinary item (Rs.)	4.87/4.87	4.31/4.31	13.90/13.90	11.96/11.96	17.32/17.31
15. Public Shareholding:					
a) Number of Shares	10,502,055	10,619,755	10,502,055	10,619,755	10,530,255
b) Percentage of Shareholding	37.31	37.73	37.31	37.73	37.41
16. Promoters and Promoter Group Shareholding	1,050,000	1,050,000	1,050,000	1,050,000	1,050,000
a) Pledged / Encumbered - No. of shares	5.95	5.99	5.95	5.99	5.96
Percentage (as a % of the total shareholding)	3.73	3.73	3.73	3.73	3.73
Percentage (as a % of the total share capital)	16,595,897	16,478,197	16,595,897	16,478,197	16,567,697
b) Non - encumbered - No. of shares	94.05	94.00	94.05	94.00	94.04
Percentage (as a % of the total shareholding)	58.96	58.54	58.96	58.54	58.86
Percentage (as a % of the total share capital)					

The above un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Monday, the 14th February, 2011. The stand-alone results are available on the company's website www.natcopharma.co.in as well as at the Registered Office of the Company. There are no exceptional and extraordinary items to be reported for the period under review. In respect of matters referred to in the limited review report by the Auditors relating to non-accounting of minimum alternative tax credit amounting to Rs. 357.73; Rs. 994.09 and Rs. 1606.08 lakhs for the quarter ended on 31st December, 2010, nine months ended on 31st December, 2010 and for the year ended 31st March, 2010 respectively, the company will review the position at the end of the financial year ending 31 March 2011.

Dated at Hyderabad, this, the 14th February, 2011.

for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2010

Pending as on 01-10-2010	Nil
Received during the quarter	56
Resolved during the quarter	56
Pending as on 31-12-2010	Nil



Report of segment wise Revenue, Results and Capital Employed, under Clause 41 of the Listing Agreement, for the quarter ended on 31st December, 2010


₹ lakhs

Particulars	Three months ended on 31 st December, 2010 (Reviewed)	Corresponding three months in the previous year	Year to date figures for the current year	Year to date figures for the previous year	Previous Accounting Year (2009-2010)
1. Segment Revenue (net sales / income, including Sales Tax)					
a) Bulk Chemicals	2844	2537	8600	7186	9793
b) Formulations	5461	5258	17646	14623	20230
c) Job Work	349	302	798	738	1033
d) Unallocated (Others)	808	555	1679	1931	2418
Total	9462	8652	28723	24478	33474
Less : Inter-segment Revenue	337	311	1101	855	899
Net Sales / Income from Operations	9125	8341	27622	23623	32575
2. Segment Results : Profit (+) / Loss (-) before tax and interest					
a) Bulk Chemicals	243	194	788	609	808
b) Formulations	2269	2388	7173	6001	8204
c) Job Work	254	245	630	585	833
d) Unallocated (Others)	505	555	1375	1879	2366
Total	3271	3382	9966	9074	12211
Less : a) Interest	345	386	1107	1146	1469
b) Other un-allocable expenditure net of un-allocable income	1231	1404	3871	3567	4656
Total Profit before Tax	1695	1592	4988	4361	6086
3. Capital Employed (Segment Assets – Segment Liabilities)					
a) Bulk Chemicals	13629	9189	13629	9189	9891
b) Formulations	9578	21699	9578	21699	21637
c) Job Work	-	-	-	-	-
d) Unallocated (Others)	10487	-	10487	-	-
Total	33694	30888	33694	30888	31528

The above report of segment-wise revenue, results and capital employed for the three months ended on 31st December, 2010 was considered and taken on record by the Board of Directors at a meeting held at Hyderabad, on Monday, the 14th February, 2011.

Dated at Hyderabad, this, the 14th February, 2011.

for and on behalf of the Board of Directors,
NATCO Pharma Limited,


V. G. Nannapaneni
Chairman & Managing Director

NATCO Pharma Limited
Regd. Office : NATCO House,
Road # 2, Banjara Hills,
Hyderabad : 500 033